Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)

Next Previous
Trial Profile

Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Tosedostat (Primary) ; Azacitidine; Azacitidine; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 29 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 17 Apr 2015 Status changed from active, no longer recruiting to recruiting as per M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top